This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Multiple sclerosis (MS)	Semaphorin 3A (SEMA3A)	Rat studies suggest that antagonizing SEMA3A could help increase remyelination to treat MS. In a rat model of CNS remyelination, SEMA3A inhibited oligodendrocyte precursor cell (OPC) differentiation and axonal remyelination compared with vehicle. Ongoing work includes elucidating the molecular mechanisms by which SEMA3A inhibits OPC differentiation. SciBX 4(11); doi:10.1038/scibx.2011.317 Published online March 17, 2011	Patented by the Medical University of Vienna; available for licensing or partnering	Syed, Y.A. <i>et al. J. Neurosci.</i> ; published online March 9, 2011; doi:10.1523/JNEUROSCI.4930-10.2011 Contact: Mark R. Kotter, University of Cambridge, Cambridge, U.K. e-mail: mrk25@cam.ac.uk